

URGENT
PRESS RELEASE



Wockhardt Limited

Corporate Office:
Wockhardt Towers
Bandra Kurla Complex
Bandra (East), Mumbai 400 051, India
Tel.: 91 22 2653 4444
Fax: 91 22 2653 4242
Website: www.wockhardt.com

Wockhardt launches Prostate drug Tamsulosin capsules in the United States

Mumbai, April 28, 2010

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing the 0.4mg capsules of Tamsulosin hydrochloride which is used for treating benign prostatic hyperplasia (BPH or non-cancerous enlargement of prostate). Tamsulosin is the generic name for the brand Flomax®, marketed in the United States by Boehringer Ingelheim. The patent on this product expired on April 27, 2010, and Wockhardt USA launched the product immediately, upon approval.

“Launching new products on the day of patent expiration is a critical factor for success in the US generic market, and Wockhardt has been consistently striving to achieve this” said Wockhardt Chairman Habil Khorakiwala. “Wockhardt has already entered into supply contracts with several customers in the US for this product. Products involving Drug Delivery Technology, like Tamsulosin capsules, remain a focus area for Wockhardt”, he further added.

According to IMS, the total market for Tamsulosin capsules in the US is about \$1,650 million and is one of the most used drugs to treat BPH. Prostate enlargement is a common condition afflicting many men above a certain age and with the growing population of the elderly in the US, the demand will continue to increase.

In the US generic pharmaceutical market, Wockhardt has been consistently growing market shares for all its products. Like in the case of Tamsulosin, it has been the endeavor of Wockhardt to be amongst the first-to-market companies for its new products.

The Tamsulosin capsules are manufactured at the US FDA certified formulation plant at Chikalthana, Aurangabad and it will use API which is also being manufactured by Wockhardt in its FDA approved plant. Both the API and the capsules were developed in-house.

Wockhardt is one of the few companies with end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API's, the dose forms and marketing through the wholly-owned subsidiary in the US, enabling the company to capture maximum value.

Wockhardt Limited is a technology-driven pharmaceutical and biotechnology company with an active multi-disciplinary research programme employing 400 scientists. Its new drug discovery programme has yielded several promising new molecules, one of which is now in Phase II human clinical trials. The US and European Union contribute to half of Wockhardt's sales.

For more information, visit www.wockhardt.com

Flomax® is a registered trademark of Astellas Pharma, Inc.